Method for prediction of biocontrol efficiency of heart rate variability taking into account peripheral blood interleukin-6

FIELD: medicine.

SUBSTANCE: peripheral blood serum interleukin-6 is measured by an immunoassay; if the measured level is more than 5 pg/ml, a biocontrol session of the heart rate variability is predicted to be effective and is expected to represent the total spectrum power gain of the heart rate variability combined with a drop in a regulatory system strain index in relation to references.

EFFECT: method enables the more accurate prediction of the length of the biocontrol course in order to intensify the vagal effect on the heart rate.

1 tbl

 

1. Scope.

The invention relates to medicine, namely to the field predict the success of implementation of corrective measures in the treatment of cardiovascular diseases. Also the invention can be used for prevention of psychosomatic disorders, which are based on the violation of the nervous regulation of cardiac functions. The invention will allow a more accurate prognosis for patients the duration of the course correction neurovegetative disorders method of biofeedback parameters of heart rhythm.

2. The level of technology.

Background state, which formed a cardiovascular disease is reduction of reserves vagal regulation of cardiac activity, which can be diagnosed by reduced overall HRV and respiratory component. Low heart rate variability is a harbinger of sudden cardiac (coronary) death, upon which violated the regulatory context in the "brain-heart" (Hugo D. Critchley, 2005). Method of biofeedback parameters of heart rate variability (HRV), known abroad as "heart rate variability (HRV) biofeedback, seeks to increase the overall heart rate variability and thereby to optimize functions such as cardiovascular and Central nervous systems (Wang, 2010; Lehrer, Vschillo, 2003). It is established that the sessions of neurofeedback with the goal of improving overall heart rate variability cause not only a decrease in blood pressure (BP), but also the optimization of the higher nervous centres (McGrady, 2010; Moravec, 2008; Demin, 2012).

A single session of relaxation with biofeedback on the index of tension of regulatory systems showed a distinct tendency to increase the stability of the examinee to emotional stress. Developed personal and psychophysiological criteria stressoustojchivosti underlying the allocation groups "hypersensitive response" and "hyporeactive", allow us to determine the specific indications for the practical use of adaptive biocontrol parameters of heart rate variability and to predict its effectiveness (Efimova, 2007; Krasilnikova, 2005). In General, a single session of neurofeedback is regarded as the test for determining adaptive capacity (Powers, 2001; Guijt, 2007).

In the correction of autonomic balance by training machine in acute myocardial infarction as a controlled parameter the researchers Armas, Suvorov, (2012) used the envelope cardiotocogram within 2 minutes including the initial psychophysiological state. The duration of the course of cardiorespiratory training a similar way�m in patients with acute myocardial infarction predicted according to echocardiography, history and success of previous sessions of neurofeedback (Armos, 2014). Widely used training machine on the operating parameter heart rate (stark et al., 2004; Redko, 2010), the standard deviation of cardiosterol (Brezovska, 2002). However, the end result of autonomic shift with this methodical approach of the predominance of vagal or sympathetic effects on the heart rhythm may be different (Gileva, 2013; Brezovska, 2002).

A measure of the total power spectrum of HRV as a managed option seems to be promising for use to enhance vagal influences on the heart rate. It is known that at short recordings (5 minutes) this indicator is similar to the standard deviation of the time of cardiosterol physiological sense - enhancing vagal activity (Baevsky et al., 2001). Indicator Total power, TP (total power spectrum of HRV) reflects mainly the amount of oscillation high-, low - and extremely low-frequency waves classic ranges and minimum share of non-periodic waves. Unlike this indicator time indicator total HRV (heart rate and evaluation options variance) have a high proportion of non-periodic waves, due to the nonstationary wave processes card�of ritmogrammy during biofeedback. So the TP for short records is clearer in terms of assessing vagal influences on heart rhythm, especially if this is accompanied by the decrease of the index of tension of regulatory systems (Baevsky et al., 2001). It is shown that the ability of biofeedback to improve the overall power spectrum of HRV in the standard short recording (5 minutes) can be viewed as a test of detection of intact vagal reserves of vegetative regulation of cardiac activity in individuals with high blood pressure. Regardless of the baseline blood pressure controlled increasing reserves of vagal regulation helps reduce blood pressure (especially systolic) at the first session biofeedback training. The degree of success of biocontrol parameters of heart rhythm in the first session may define further individual strategy of self-regulation (duration of sessions, frequency of their conduct) that will make the patient a more active participant in the ongoing comprehensive physician therapy of arterial hypertension (Pokotilov, 2013). The success of biofeedback parameters of heart rate with the aim of increasing the total power spectrum of HRV also predict on the basis of baseline characteristics of temperament - plasticity, arginate, pace and emotion (Krivonogov, 2013).

While�researchers internal environment of the body can also cause the effects of biofeedback parameters of heart rhythm. So, it has been shown that in patients with arterial hypertension on the background of a relative deficiency of serotonin in serum, the success of biofeedback parameters heart rate less expressed than in individuals with optimal levels of serotonin in the blood (Pokotilov, 2012). The role of bioregulators, providing efficient intersystem interaction in the human body, also perform cytokines. Interleukin-6 (IL-6) provides important regulatory functions not only in the realization of inflammatory reactions, but also in the regulation of certain parts of metabolism, neuroimmune and neuro interactions (Naitoch, 1988; Ivanov, 1999). While traditionally viewed pathophysiological role of high concentrations of IL-6 in individuals with cardiovascular, endocrine diseases, metabolic syndrome. However, there is increasing evidence of the important regulatory role of IL-6 deficiency in the body leads to the formation of a number of pathological phenomena. So, it is revealed that deficiency of IL-6 leads to a decrease in the level of neuroprotective antioxidants, which in turn enhances oxidative stress, the signs of which were recorded in the tissue of the brain stem inflammation (Penkowa, 2000). IL-6 plays an important role in maintaining the integrity of blood-brain barrier, nedostatok� this cytokine can enhance the manifestation of convulsive reactions in the pathology of the Central nervous system (Pedchenko, 1999). The experiment also shown that mice with deficiency of IL-6 due to the presence of a null mutation of the corresponding gene showed low levels of motor and cognitive activity, as well as a higher level of emotional reactivity in comparison with mice from the control group who had normal IL-6 level (Armario, 1998). To develop biomarkers of certain personality traits in humans. Found that people with high levels of neuroticism in combination with high level of integrity (honesty) of the IL-6 level in the blood significantly lower than in people with other combinations of data personal characteristics (Turano, 2012).

The above data indicate a high biological significance of IL-6 in neuroimmune interactions, providing the optimum level of organization of the higher nervous functions, cognitive and emotional sphere. The biological significance of the deficiency of interleukin-6 is the fundamental basis for the proposal of methods of diagnosis and treatment of several diseases using information about the content of this cytokine in the blood.

Thus, recombinant IL-6 can be used as a diagnostic test to assess the functional integrity of the hypothalamic-pituitary-adrenal system (Ivanov, 1999; Mastoracus, 1993). Predlozhennogo predicting the risk of implementation of perinatal lesions of the Central nervous system in the neonatal period in term infants, born in a state of asphyxia - the lower the level of proinflammatory cytokines, in particular IL-6 in the blood of these children, the higher the risk of developing neurological disorders (Chistyakova, 2012). For the correction of cognitive impairment in humans and animals prompted to enter inflammatory mediators (including IL-6), their functional fragments or amphetamine production of such mediators methods intracranial infusions, and other ways in which these substances are able to penetrate the blood-brain barrier (Potter et al., 2012). This method is intended to compensate for cognitive loss in people with traumatic brain injuries, cerebral stroke and other diseases of the Central nervous system. With the aim of achieving a slimming effect you can use cosmetic composition containing a substance inducing the production of IL-6. This ensures the outflow of fatty acids accumulated in the adipocytes, and inhibition of admission to these new cells fatty acids (Casella et al., 2005).

Thus, in the presented methodological approaches for evaluating the success and effectiveness of the biofeedback sessions, as well as in predicting the effectiveness is not taken into account the initial level of immune parameters. However, modern fundamental and practical development in the field of Neuroimmunology and Fi�eologie of self-regulation using biofeedback are the prerequisites for developing a method of forecasting the success of biofeedback parameters of heart rate in humans to the reference level of his IL-6 in peripheral blood.

3. Summary of the invention. Disclosure of the invention.

In the framework of the clinical examination of the study included 76 people (28 men and 48 women) aged from 30 to 53 years. The group included both healthy individuals and individuals with arterial hypertension of 1-2 degrees with stable disease, with a risk factor of complications 1-2. Exclusion criteria were acute and chronic infectious diseases, traumatic brain injury, a history of paroxysmal epileptic origin, autoimmune disease, organic heart disease and blood vessels, disorders of heart rhythm.

In the morning on an empty stomach in humans produced the blood from the cubital vein for subsequent determination in serum by ELISA the level of interleukin-6 (""Biohimmak", Russia) using the analyzer Multiskan, Finland).

She later produced a record of cardiotocogram by means of the device "varikard" ("Ramen", Russia) for 5 minutes. Evaluated the performance of heart rate variability - HRV (Bayes) such as:

- heart rate (HR), beats/min;

- the index of tension of regulatory systems - JN (JN=AMO/mo×MxDMn where AMO% - amplitude fashion, Mo - fashion, MxDMn - variation of the amplitude of RR values in the dynamic range) as an indicator of sympathetic activity;

- RMSD (root mean sum successful lines of RMS differential characteristic of the entire volume of cardio intervals as an indicator of parasympathetic activity of autonomic regulation;

- TP (Total Power), MS2- total power spectrum of fluctuations of the duration of RR-intervals as an indicator of the predominance of parasympathetic influences on the heart rate.

For the implementation of the principle of biological feedback (BFB) during a single session examined within 5 minutes received on the monitor screen the status of the total power spectrum of HRV (Total Power) with the metric refresh every 4-5 seconds. The man picked up his graphic line representing the change of the parameter TR, varied with slope up (increase value). A person applied the strategy of "free search" - a combination of relaxed deep breathing with an effective smooth exhalation, muscle relaxation and the creation of positive emotional mental images (patent 2317771 RU). In subsequent evaluated the performance of the HRV. A criterion of success of biofeedback training was considered the final increase in total power of HRV spectrum in combination with the decrease in the index of tension of regulatory systems relative to background values. In case of increase IN, decrease in PR, and an isolated increase in TR or reduction IN regards this Sean� biofeedback as unsuccessful. After the biofeedback training session were recorded background recording of cardiointervalogram are conducted without biofeedback (5 minutes).

Statistical processing of obtained results was performed using nonparametric methods with the help of computer software package Statistica 6.0 (StatSoft, USA). Take into account the median (Me) and interquartile range at 25% and 75% levels of the sample values. For testing the statistical hypothesis of intergroup differences was used for two samples the criterion χ-squared test with rank variance analysis (p<0.05) and for two dependent samples the Wilcoxon test (p<0.05) and also for two independent samples the Mann-Whitney test (p<0,05).

The degree of success of biocontrol parameters of heart rate in the sample of individuals considered depending on the initial level of IL-6 in peripheral blood (range of values in the sample from 3,24 to 28 PG/ml). A dedicated group with indicators of IL-6 less than 5 PG/ml (21 people; 5 men and 16 women - group I) and the group with optimal performance of the IL-6 - more than 5 PG/ml (53; 23 men and 30 women - group II). People with high levels of IL-6, reflecting the state of acute inflammation (50 PG/ml) not detected. The average age and percentage of men and women in the groups were statistically similar (p>0,05).

It was found that initial mean levels of HRV was� statistically similar in groups although a higher rate IN showed a trend of an increasing sympathetic tone in patients of group I (table).

However, after a session of neurofeedback to enhance vagal influences on the heart rate in the group with low IL-6 level indicators of sympathetic activity were significantly higher than in patients of group with the optimal level of IL-6. The comparison of the two groups showed that the indicators IN HR and became significantly higher, and TR indicators and RMSSD - significantly lower in patients of group I than group II. In patients of group I, a significant increase in RMSSD, indicating vagal activity after biofeedback training in comparison with the background value was not revealed. This phenomenon is due to the fact that in the group with a relative deficiency of IL-6 (group I) revealed the greatest number of people with failed result of biofeedback training. Failure is the result of neurofeedback for individuals with a deficiency of IL-6 was detected in 12 out of 21 (57%). This percentage was significantly higher (p=0.006) than among those with optimal levels of IL-6 - 13 of 53 (24%).

Thus, the technical result provided by the present invention is to increase the total power spectrum of HRV in combination with a reduction IN as a result of the biofeedback session parameters of heart rate variability during �slowie, that the initial level of IL-6 in peripheral blood will be more than 5 PG/ml.

4. The implementation of the invention. Examples.

Example 1. Patient K., 48 years old, with complaints of headache, meteosensitivity, with a diagnosis of hypertension 1 degree, a risk factor for complications 1-2. HELL in patients receiving beta-blockers 122/88 mm Hg.St.; Heart rate of 79 beats/min. the Levels of Il-6 in the blood 3,48 PG/ml. HRV Indices in the background: RMSSD - 22 MS, YING - 161 CONV. units, TR - 1823 MS2. The forecast has been made about the failure of a session of neurofeedback to enhance vagal influences on the heart rate.

After a session of neurofeedback: BP 120/86 mm Hg.CT., Heart rate 80 beats/min; RMSSD - 9 MS, YING - 649 CONV. units, TR - 607 MS2. The prediction of the failure of biofeedback session confirmed - there was a decrease in TR instead of the expected increase and the increase IN instead of falling as expected.

Example 2. Patient D., 48 years of age, with a diagnosis of hypertension 1 degree, a risk factor for complications 1-2. The level of interleukin-6 in the blood of 3.64 PG/ml. HELL in patients receiving antihypertensive drugs (perindopril erbumine) in the initial state 157/110 beats/min; heart rate 78 beats/min; the indices of HRV: RMSSD - 13 MS, YING - 170 beats/min; TR - 1407 MS2. The forecast has been made about the failure of a session of neurofeedback to enhance vagal influences on the heart rate.

After a session of neurofeedback: the HELL - 137 mm Hg.CT., Heart rate is 76 beats/min, RMSSD - 15 MS, IN - 184 CONV. units, TR - 1150 MS2 . The prediction of the failure of biofeedback session confirmed - there was a decrease in TR instead of the expected increase and the increase IN instead of falling as expected.

Example 3. A patient, 48 years of age, with a diagnosis of hypertension 1 degree, a risk factor for complications 2. The level of interleukin-6 in blood 7,90 PG/ml. HELL in patients receiving antihypertensive drugs (lorista) in the initial state 158/101 mm Hg.t., Heart rate is 73 beats/min, RMSSD - 36 MS, YING - 60 CONV. units, TR - 2887 MS2. The forecast about the possible success of a session of neurofeedback to enhance vagal influences on the heart rate. After a session of neurofeedback: the AD - 156/97 mm Hg.CT., Heart rate is 62 beats/min, RMSSD - 40 MS, IN - 56 CONV. units, TR - 5582 MS2. A prediction about the success of the session biofeedback was confirmed - there was an increase in TP and a decrease IN.

Example 4. Female P., 41, a state of emotional tension. The level of interleukin-6 in blood 13,60 PG/ml. HELL 106/66 mm Hg.CT., Heart rate 82 beats/min, RMSSD - 14 MS, YING - 686 CONV. units, TR - 413 MS2. The forecast about the possible success of a session of neurofeedback to enhance vagal influences on the heart rate.

After a session of neurofeedback: the AD - 98/66 mm Hg.CT., Heart rate is 84 beats/min, RMSSD - 18 MS, JN - 207 CONV. units, TR - 1314 MS2. A prediction about the success of the session biofeedback was confirmed - there was an increase in TP and a decrease IN.

2. The forecast about the possible success of a session of neurofeedback to enhance vagal influences on the heart rate.

After a session of neurofeedback: the AD - 121/75 mm Hg.CT., Heart rate is 73 beats/min, RMSSD - 51 MS, JN - 66 CONV. units, TR - 6415 MS2. A prediction about the success of the session biofeedback was confirmed - there was an increase in TP and a decrease IN.

The advantages of presented method.

Unlike other factors accounting for the original state of man that determines his success in the implementation of the biofeedback session parameters heart rate (characteristics of temperament, the level of serotonin in the peripheral blood) the method enables to take into account in this kind of activity baseline levels of the regulatory cytokine IL-6 in peripheral blood in humans. The proposed method will allow to determine the forecast the duration of the course of sessions of neurofeedback to enhance vagal influences on the heart rate. In individuals with signs of deficiency of IL-6 in peripheral blood correction of altered autonomic tone method of biofeedback may take a longer time in comparison with individuals with optimal levels of IL-6. Individuals with deficiency of IL-6 are well�be given a more in depth immunological examination and conduct a course of immunocorrection, to help optimize neurovisceral communication and contribute more in the future successful implementation of training machine.

5. Sources of information

1. Analysis of heart rate variability using different electrocardiographic systems (guidelines) / P. M. Baevsky, G. G. Ivanov, L. V. Characin and others // Bulletin of Arrhythmology. - 2001. - No. 24. - P. 65-87.

2. Brezovska N. G. Adaptive biofeedback-based biofeedback parameters on the dynamics of cardiac rhythm man: author. Diss. ... candidate. honey. science - Tomsk, 2002. - 23 p.

3. Gileva O. B. the Ability to self-regulation biofeedback in gaming and the success of students 11-13 years / Gileva O. B. // Bulletin of Siberian medicine. - 2013. - Vol. 12. - No. 2. - P. 141-146.

4. Demin D. B., Pokotilov L. V., Krivonogov E. V. Variants of EEG reactions when you perform a course of biofeedback training in adolescents depending on initial vegetative tonus // human Ecology. - 2012. - No. 3. - P. 16-22.

5. Efimova E. A. the Use of biofeedback training in the treatment of children with the syndrome of vegetative dysfunction: author. Diss. ... candidate. honey. Sciences. - Pyatigorsk, 2007. - 25 S.

6. The invention application 2011108560 EN. Methods of treating cognitive disorders. Applicant - University of South Florida (US). Authors - Potter X., Arendash G. V., Bennett, S., Boyd T. Publ. 10.09.2012. Bull. 25.

7. The invention application 2012133575 EN. �] determine the scope of the course cardiorespiratory training in patients in the early stages of uncomplicated myocardial infarction. Authors Armas I. V., Balueva S. A., Suvorov N. B. Applicant - chair of sbee HPE "northwestern state medical University n. a. I. I. Mechnikov" of Minsotszdrav of the Russian Federation. Publ. 20.02.2014. Bull. 5.

8. Ivanova M. M. the Role of interleukin-6 in the pathogenesis of human diseases // international journal of medical practices. - 1999. - No. 4. - Pp. 40-50.

9. 's biofeedback and stress - dependent condition / O. A. Anglewicz, O. G. Donskaya, A. A. Zubkov, M. B. Shtark // Bulletin SB RAMS. - 2004. №3 (313). - P. 53-60.

10. Krasilnikova M. O. Psychophysiological criteria for efficiency in the management of heart rate variability with biofeedback: Diss. ... candidate. honey. Sciences. - Volgograd, 2005. - 129 p.

11. Patent 2258500 EN. A cosmetic composition for slimming containing a substance inducing the production of IL-6. Authors - Casella P., Derek J. M., Hesna J. Patentee - Sanofi-Aventis (FR). Publ. 20.08.2005. Bull. No. 23.

12. Patent 2465595 EN. A method of predicting risk of implementation of perinatal lesions of the Central nervous system in the neonatal period in term infants born in a state of asphyxia. Authors Chistyakova G. N., Remizova I. I., Bychkova S. V., etc. the Patent - FGU "Ural research Institute of maternity and infancy Minsotszdrav of the Russian Federation. Publ. 27.10.2012. Bull. No. 30.

13. Patent 2465816 EN. The method of correcting vegetative�CSOs balance in patients with myocardial infarction. Authors Armas I. V., Suvorov N. B., Balueva S. A. the Patent - sbei HPE "northwestern state medical University n. a. I. I. Mechnikov" of Minsotszdrav of the Russian Federation. Publ. 10.11.2012. Bull. No. 31.

14. Patent 2477619 EN. A method of predicting the effectiveness of biofeedback parameters of the heart with the dynamic properties of personality. Authors Krivonogov E. V., Pokotilov L. V. the Patentee is the research science Institute of physiology of natural adaptations, Ural branch of RAS. Publ. 20.03.2013. Bull. No. 8.

15. Patent RU 2317771. Method of correction of autonomic imbalances with the help of a complex for processing of cardiointervalogram and analysis of heart rate variability "varikard 2.51" running a computer program ISCIM 6.1 (BUILD 2.8), using biofeedback. Authors Pokotilov L. V., Semenov Yu. The patent - Institute of environmental physiology, Ural branch of RAS. Publ. 27.02.2008.

16. Pokotilov L. V., Demin D. B., Krivonogov E. V. Diev, M. N., Khasanova N. M. The success of biofeedback parameters of heart rate variability in individuals with different levels of blood pressure // Vestnik of the Russian Academy of medical Sciences. 2013. - No. 7. - P. 20-23.

17. Pokotilov L. V., Khasanova N. M. Dieva M. N., Krivonogov E. V., Demin D. B., O. A. Stavinsky, Yakushkin S. N. The role of serotonin in the neurovegetative changes of indicators in the biofeedback parameters vari�analysis of spectral values of the heart rate in individuals with different levels of blood pressure // Fundamental research. 2012, vol 9 (4), pp. 827-830.

18. Redko N. G. The dynamics of psycho-vegetative parameters depending on the properties of temperament in teaching self-regulation in patients with arterial hypertension / N. G. Redko // Bulletin SB RAMS. - T. 30. - №6. - 2010. - P. 52-56.

19. A pilot study of one - session biofeedback training in pediatric headache / S. W. Powers, M. J. Mitchell, K. C. Byars, et al. // Neurology. - 2001. - Vol.56. - P. 133.

20. Big 5 personality traits and interleukin-6: Evidence for "healthy Neuroticism" in a US population sample / Nicholas A. Turiano, Daniel K. Mroczek, Jan Moynihan, Benjamin P. Chapman. // Brain, Behavior, and Immunity - 2012 - Vol.28 - P. 83-89.

21. Effect of slow abdominal breathing combined with biofeedback on blood pressure and heart rate variability in prehypertension / S. Z. Wang, S. Li, X. Y. Xu et al. // Journal of Alternative & Complementary Medicine - 2010 - Vol.16(10) - P. 1039-1045.

22. Guijt A. M. Test - retest reliability of heart rate variability and respiration rate at rest and during light physical activity in normal subjects / A. M. Guijt, J. K. Sluiter, M. H. Frings - Dresen // Arch. Med. Res. - 2007. - Vol.38(1). - P. 113-120.

23. Heart Rate Variability Biofeedback Increases Baroreflex Gain and Peak Expiratory Flow / Paul M. Lehrer, Evgeny Vaschillo, Bronya Vaschillo at al. // Psychosomatic Medicine - 2003 - Vol.65 - P. 796-805.

24. IL-6 deficiency leads to increased emotionality in mice: evidence in transgenic mice carrying a null mutation for IL-6 // A. Armario, J. Hernandez, H. Bluethmann, and J. Hidalgo // Journal of Neuroimmunology - 1998 - Vol.92(1-2) - P. 160-169.

25. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats / Y. Naitoh, J. Fukata, T. Tominaga, et al. // Biochemical and biophysical research communication. - 1988. - Vol.155. - C. 1459-1463.

26. Mastorakos G., Chrousos G., Weber J. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans // The Journal of Clinical Endocrinology and Metabolism. - 1993. - Vol.77. - P. 1690-1694.

27. McGrady A. The effects of biofeedback in diabetes and essential hypertesion / A. McGrady // Cleveland Clinic Journal of Medicine - 2010 - Vol.77 - Suppl. 3 - S. 68-71.

28. Mental stress and sudden cardiac death: asymmetric midbrain activity as a linking mechanism / Hugo D. Critchley, Peter Taggart, Peter M. Sutton et al. // Brain - 2005 - Vol.128 (1) - P. 75-85.

29. C. S. Moravec Biofeedback therapy in cardiovascular disease: Rationale and research overview / C. S. Moravec // Cleveland Clinic Journal of Medicine - 2008 - Vol.75 - Suppl. 2 - S. 35-38.

30. Pedchenko, T. V., Le Vine S. M. IL-6 deficiency causes enhanced pathology in Twitcher (globoid cell leukodystrophy) mice. // Experimental Neurology - 1999 - Vol.158 (2) - P. 459-68.

31. Penkowa M, Hidalgo and J. IL-6 deficiency leads to reduced metallothionein - I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment // Experimental Neurology. - 2000 - Vol.163(1) - P. 72-84.

Method of predicting the efficacy of biofeedback parameters of heart rate variability based on the level of interleukin-6 in peripheral blood, characterized in that people determine the level of interleukin-6 in peripheral blood serum by ELISA; when its level is more than 5 PG/ml predict the success of biofeedback session parameters of heart rate variability in the form of increased total power spectrum of heart rate variability in combination with the decrease in the index of tension of regulatory systems in comparison with the original values.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to field of biotechnology and immunology. Described is antibody, which specifically binds denatured CD70. Claimed group of inventions can be used in medicine.

EFFECT: disclosed is method of diagnostics, prediction, prevention and treatment of malignant tumours of ovaries, pancreas and other malignant tumours with application of antibodies.

5 cl, 10 dwg, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used for the ex-vivo determination of the cancer treatment efficiency. For this purpose, a level of activated T-lymphocytes (CD3+ CD69+) in an organism is measured after the introduction to a subject of one or more doses of an immunogenic composition. The level of the activated T-lymphocytes (CD3+ CD69+) higher than approximately 10.4% testifies to the fact that the subject is such that demonstrates successful clinical outcome for treatment; that is an increase of the survival rate.

EFFECT: application of the level of the activated T-lymphocytes (CD3+ CD69+) makes it possible to apply them as a biomarker for the monitoring, modification or correction of cancer treatment.

7 cl, 1 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to immunology and represents a method for anti-immunoglobulin E antibody neutralisation activity test, which consists in binding the test antibodies with human IgE in a solution, incubating the above solution with human peripheral blood, inducing cell degranulation and determining a cell portion having a high expression level of CD63 (CD63high) surface marker in a basophile population with phenotype CD123+HLA-DR-.

EFFECT: invention enables considerably reducing the length of analysis and its labour intensity.

2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention aims at treating drug-induced dry eye syndrome (DI-DES). Treating DI-DES implies taking the past medical history, measuring tear production and eye xerosis values reduced and increased respectively in relation to the norm. Unpreserved ocular hypotensive medications are prescribed in the patient. Unpreserved artificial tears are also applied. The lachrymal fluid is analysed by a multicytokine technique. If the analysis shows increased concentrations of proinflammatory cytokines - interleukin-6, interleukin-8, interleukin-12, Th-1 - interleukin-2, interferon-gamma, and Th-2 - interleukin-4, by min 30% in relation to the patient's age norm, a chronic immune ocular inflammation is detected. That requires transpalpebral Blepharogel-1 phonophoresis and 1% hydrocortisone ointment phonophoresis on the sub-mastoidal region from both sides; the therapeutic course is 8-10 daily procedures.

EFFECT: optimal conditions for diagnosing and reasoned differentiated therapy of DI-DES that enables prescribing the pathogenetically reasoned therapy in due time and increasing the efficacy of the therapeutic exposure.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: in a premature baby the concentration of neuron-specific enolase (NSE), concentration of a brain-derived neurotrophic factor (BDNF), concentration of a vascular-endothelial growth factor (VEGF) in umbilical blood and concentration of the vascular-endothelial growth factor (VEGF) in peripheral blood are determined on the basis of the enzyme immunoassay of umbilical and peripheral blood serum on the 7-th day of life, a prognostic index (PI) is calculated by formula: PI=-0.007×X1+0.006×X2-0.05×X3+0.0004×X4-3.9, where X1 is VEGF content in umbilical blood at birth (ng/ml); X2 is VEGF content in peripheral blood on the 7-th day of life (ng/ml); X3 is NSE content in umbilical blood (mcg/l); X4 is BDNF content in umbilical blood (ng/ml); Const=-3.9. When PI is higher than 0, a conclusion about the absence of risk of occlusive posthaemorrhagic hydrocephalus formation is made, and if PI is lower than 0, a high risk of the said pathology development is predicted.

EFFECT: invention makes it possible to increase the efficiency of prediction of occlusive posthaemorrhagic hydrocephalus formation in the premature children with an extremely low body weight at birth.

2 ex

FIELD: medicine.

SUBSTANCE: group of inventions relate to medicine and deals with method of diagnosing neurodegenerative disease in individual, including the following stages (i) determination of one or several parameters, selected from group, consisting of 3ab40 or value of calculated parameter, selected from group, consisting of 2ab40+3ab40, 2ab40+3ab40+2ab42+3ab42 and 1ab40+2ab40+1ab42+2ab42; (ii) comparison of parameter value with standard value, corresponding to value of said parameter in standard sample; and (iii) diagnostics of neurodegenerative disease, in case if increase of parameter value in comparison with standard value is observed. Group of inventions also deals with method of detecting stage, preceding neurodegenerative disease, method of differentiating neurodegenerative disease from stage, preceding said neurodegenerative disease.

EFFECT: group of inventions provide high sensitivity and specificity of detection methods.

13 cl, 12 ex, 14 dwg, 12 tbl

FIELD: medicine.

SUBSTANCE: patient's synovial fluid is sampled, and patient's supernatant chemokines CXCL9/MIG, CXCL10/IP-10 and CXCL11/ITAC are measured. A diagnosis of rheumatoid arthritis is diagnosed, if at least one of chemokines exceeds a threshold; the chemokine thresholds make 2625.8 pg/ml for CXCL9/MIG, 3108.2 pg/ml for CXCL9/MIG and 32.4 pg/ml for CXCL11/ITAC respectively. If the measured values are below the thresholds for three chemokines at the same time, the absence of rheumatoid arthritis and potential osteoarthrosis are stated.

EFFECT: using the given method enables differentiating rheumatoid arthritis and osteoarthrosis by measuring specific markers in the synovial fluid taken from the location directly.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to method of diagnosing rheumatoid arthritis, method of determining therapeutic agent for treatment of rheumatoid arthritis and set for realisation of methods. Methods are characterised by the fact that include stage of measuring amount of talin in plasma or serum of animal subject. Said measurement is carried out, for instance, by immunologic method with application of antibody, binding with talin. If amount of talin is higher than its average value in control subject without rheumatoid arthritis, rheumatoid arthritis is diagnosed in subject. In case of reduction of talin amount after introduction of therapeutic agent in comparison with amount of talin before introduction, therapeutic effect is stated. Set in accordance with claimed invention contains solid-phase carrier, to which antibody, binding with talin, is attached.

EFFECT: increased efficiency of diagnostics.

9 cl, 4 tbl, 4 ex, 3 dwg

FIELD: medicine.

SUBSTANCE: seromucoid concentration is measured in supernatant of a biological fluid aspirated from the nasopharynx of the newborns suffering a generalised form of the intrauterine mono-cytomegalovirus infection or mixed cytomegalovirus infection. If the seromucoid concentration is 0.110-0.140 absorbance units, the early stage of the generalised form of the intrauterine mono-cytomegalovirus infection is diagnosed. If the seromucoid concentration is 0.141-0.171 absorbance units, the early stage of the generalised form of the intrauterine mixed cytomegalovirus infection caused by a combination of the cytomegalovirus and type 1 herpes simplex virus is diagnosed.

EFFECT: using the declared method enables the effective differential diagnosis of the generalised form of the intrauterine mono or mixed cytomegalovirus infection in the newborns.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to biotechnology. There are presented versions of a humanised anti-CD79b antibody, each of which is characterised by the presence of a light and heavy chain and a set of 6 CDR with a specified amino acid sequence and at least one free cysteine amino acid residue specified in A118C (according to the European Numeration) in the heavy chain and V205C (according to the Kabat numeration) in the light chain. There are disclosed: versions of a conjugate compound of the antibody and a drug preparation, wherein the antibody is bond to the drug preparation through free cysteine; an antibody-based pharmaceutical compound for treating cancer; method for detecting CD79b or cancer cells, as well as a method for inhibiting cell proliferation using the conjugate compound. What is described is a method for producing the conjugate compound.

EFFECT: invention can find further application in the therapy of CD79b-associated cancer diseases, including treating haemopoietic tumours in mammals.

70 cl, 20 tbl, 9 ex, 51 dwg

FIELD: medicine, ophthalmology.

SUBSTANCE: in lacrimal liquid one should detect the content of interleukin 8 (IL-8) and that of interleukin 1 beta (IL-1β) to calculate prognostic coefficient (PC) due to dividing the first value by the second one by the following formula: At PC value being below 10.0 one should predict favorable disease flow, and at PC value being above 10.0 - unfavorable flow.

EFFECT: higher accuracy of prediction.

2 ex

FIELD: medicine, medicinal microbiology.

SUBSTANCE: method involves growing microorganism culture to be studied in solid nutrient medium followed by preparing microbial suspension and its incubation in the presence of lactoferrin. Control sample is prepared in parallel series. Control and experimental samples are incubated, supernatant is removed from bacterial cells and lactoferrin concentration is determined in supernatant of experimental and control sample by immunoenzyme analysis. Then anti-lactoferrin activity is calculated by difference of concentrations of residual lactoferrin in experimental and control samples. This method provides enhancing the sensitivity and precision in carrying out the quantitative evaluation of anti-lactoferrin activity in broad spectrum of microorganisms that is urgent in diagnosis and prognosis of diseases with bacterial etiology. Invention can be used in determination of persistent indices of microorganisms for assay of their etiological significance in pathological processes.

EFFECT: improved assay method.

3 tbl, 3 ex

FIELD: medicine, biology.

SUBSTANCE: invention relates to nutrient medium used for accumulation of cells for the following cytological and/or immunocytochemical analysis carrying out. Invention relates to medium containing salts NaCl, KCl, anhydrous CaCl2, MgSO4 x 6 H2O, MgCl2 x 6 H2O, Na2HPO4 x 2 H2O, KHPO4, NaHCO3, and also glucose and Henx's solution, 10% albumin solution and polyglucin taken in the ratio 1:1:1. Invention provides enhancing the preservation of cells.

EFFECT: improved an valuable properties of nutrient medium.

3 ex

FIELD: medicine, cardiology.

SUBSTANCE: in peripheral blood one should detect the level of CD95(+) and CD16(+) neutrophilic granulocytes and at combination of increased level of CD95(+) neutrophilic granulocytes by 4 times and more and CD16(+) neutrophilic granulocytes by 0.6 times against the norm with ECG signs of myocardial infarction one should predict lethal result of large-focal myocardial infarction.

EFFECT: higher accuracy of prediction.

FIELD: medicine, parasitology.

SUBSTANCE: one should carry out immunoenzymatic assay to detect diagnostic optic density and that of labeled immune complex in a plot's hole with tested serum measured in conventional units at wave length being 492 nm. One should calculate coefficient of antibodies concentration measured in conventional units by the following formula: CAC = (Odtsh - Odd) x 100, where CAC - coefficient of antibodies concentration, Odtsh - optic density of the hole with tested serum, Odd - diagnostic value of optic density, 100 - coefficient of serumal dilution. By CAC value one should detect the titer of antibodies to Lamblia intestinalis antigens to interpret results of the trial. The method enables to study the dynamics of disease flow.

EFFECT: higher efficiency and accuracy of diagnostics.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with studying and treating diseases of inflammatory, autoimmune and degenerative genesis. One should perform sampling of heparinized blood followed by its sedimentation to obtain blood plasma with leukocytes and centrifuging to isolate the latter which are washed against erythrocytic and serumal admixtures, and, also, it deals with calculating the number of cells in samples out of leukocytic suspension after incubation (B) for 1.5 h at 37 C in holes of plastic microplotting board, out of leukocytic suspension one should additionally prepare two samples, one should be applied to calculate total number of leukocytes before incubation (A), the second sample undergoes incubation at the same mode at addition of autoserum to calculate the number of cells remained after incubation (C). One should state upon adhesive properties of leukocytes by the index of spontaneous adhesion (D), where D=(A-B)/B.100%, and effect for enhanced cellular adhesion under the impact of autoserum should be detected by the value of K=(B-C)/C.100% at K ≥ 30%, where B - C - the number of cells undergone additional adhesion after addition of autoserum. The present innovation widens functional possibilities of the suggested method due to obtaining additional values depicting adhesive properties of blood leukocytes.

EFFECT: higher accuracy of detection.

FIELD: medicine, immunology.

SUBSTANCE: one should carry out reaction of blast-transformation, detect proliferation of T-lymphocytes activated with antibodies to CD3 in the presence of interleukin-7 (ACT IL-7) and in the presence of interleukin-7 and dexametazone (ACT IL-7 D), calculate the index for dexametazone action as the ratio of ACT IL-7 to ACT IL-7 D, moreover, the value of dexametazone action index being above 1.2 indicates increased production of cytokins that suppress T-lymphocytes in neonatals. The method enables to detect functional defect of immune system that characterizes neonatal period.

EFFECT: higher efficiency of detection.

2 ex

FIELD: medicine.

SUBSTANCE: method involves measuring forced exhalation volume per 1 s (FEV1) in l, full right ventricle evacuation time (RVE) in ms and angiotensin II value (AII) in ng/l. Discriminant relationship is built as D=0.504·RVE+3.038·FEV1 - 2.0·AII. D being less than 83.88, pulmonary hypertension occurrence is predicted within 1 year. D being equal to or greater than 83.88, no pulmonary hypertension is predicted to occur.

EFFECT: enhanced accuracy of prediction.

FIELD: medicine, medicinal immunology.

SUBSTANCE: method involves determination of heterophilic antibodies in human serum blood by the Paul-Bunnel's method relatively the level of circulating immune complexes, complement-activating properties of heterophilic antibodies by incubation of standardized ram erythrocytes with 0.8% serum for 30 ± 5 min and the following measurement of the erythrocytes lysis degree. The measurement of the effector function coefficient of heterophilic antibodies is carried out by the complement system Keff.f.h.a.-c.s. by the formula: Keff.f.h.a.-c.s. = Y/Tg.a. wherein Y means a lysis degree, %; Tg.a. means a reverse titer of heterophilic antibodies to ram erythrocytes. The damage assay is carried out by comparison of the immune status with the relative level of circulating immune complexes in serum. Method provides detection of preclinic from of immunodeficiency and autoimmune diseases that opens the possibility for their prophylaxis at most early stages of development. Invention can be used for assay of damage in the immune status in human serum blood.

EFFECT: improved method for assay.

5 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves concurrently examining anti-inflammatory IL-4 level in blood serum and lacrimal fluid. The value being within the limits of 60-70 pg/l in blood serum and 5-15 pg/l in lacrimal fluid, disease prognosis is considered to be unfavorable. The IL-4 concentration being within the limits of 90-100 pg/l in blood serum and 20-30 pg/l in lacrimal fluid, disease prognosis is considered to be favorable.

EFFECT: high accuracy of diagnosis.

Up!